Intentional weight loss via semaglutide among persons with heart failure and preserved ejection fraction and obesity significantly improves weight loss and health status as assessed by the KCCQ-CSS score and is associated with improvements in 6-min walk test. Ongoing and planned trials will explore the role of intentional weight loss with treatments such as semaglutide or tirzepatide for individuals with heart failure across the entire ejection fraction spectrum.
Keyphrases
- weight loss
- ejection fraction
- heart failure
- aortic stenosis
- bariatric surgery
- roux en y gastric bypass
- gastric bypass
- left ventricular
- weight gain
- cardiac resynchronization therapy
- acute heart failure
- glycemic control
- atrial fibrillation
- obese patients
- type diabetes
- physical activity
- aortic valve
- coronary artery disease
- body mass index